39 results about "Lewy bodies dementia" patented technology

The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and / or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease (mad cow disease), dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke. The present compounds are effective to treat any neurological condition where acetylcholine transmission neurons and their target cells are affected. Compounds according to the present invention are effective to alleviate and / or reverse the effects of a neurodegenerative condition, prevent further deterioration and / or enhance cognition and memory in patients suffering from neurodegenerative disorders, especially Alzheimer's disease.

The invention relates to the technical field of biology, and particularly provides a screening method of an infective gene capture probe related to dementia, a capture genome, a product and an application. The method provides a screening condition of the capture probe. The screening condition is optimized, and the method specifically comprises restriction on the related condition of selection of atarget section, the length of the capture probe, requirements on specificity, GC content, the number of probes and the like. The infective gene capture probe related to dementia comprises coding regions of 11 genes, infective genes for detecting five kinds of diseases of Alzheimer's disease, frontotemporal dementia, dementia related to Parkinson's diseases, dementia related to amyotrophic lateralsclerosis and lewy body dementia can be realized, and reference can be provided for molecular genetics diagnosis of ill individuals, screening of familial Alzheimer's diseases, frontotemporal dementia, the dementia related to Parkinson's diseases, the dementia related to amyotrophic lateral sclerosis and the lewy body dementia, and corresponding heredity consultation.

The present invention is directed to arylpyrrolopyridine derivatives of formula (A)The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.

The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associated cognitive disorders, multiple system atrophy, and rare neuroaxonal dystrophies, such as Niemann-Pick type C disease (NPC) and Gaucher's disease comprising administering an inhibitor to disrupt the interaction between Aβ or αS and neuronal lipids. The invention further relates to assays for identifying agents that reduce interaction between Aβ or αS and neuronal lipids. Lastly, the invention relates to methods and compositions for intranasal administration of fatty acids or lipids containing fatty acid acyl chains of dietary lipids for promoting central nervous system health and / or prevention or treatment of neurodegenerative disorders.

The invention provides application of transferrin and transferrin combined sodium oligomannate capsule and composition containing the sodium oligomannate capsule, and in particular relates to application of the transferrin or the transferrin combined sodium oligomannate capsule to preparation of a medicine for preventing or / and improving or / and treating dementia. and the composition containing thesodium oligomannate capsule comprises the sodium oligomannate capsule and the transferrin. The invention has the beneficial effects that the transferrin can improve the cognitive level of a dementiapatient, and with the combined use of the transferrin and the sodium oligomannate capsule, the effect of the sodium oligomannate capsule to prevent, improve and treat Alzheimer's disease and other types of dementia, such as vascular dementia, frontotemporal dementia, lewy body dementia,dementia caused by brain traumas and dementia caused by neuroinflammation, is further improved.

The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease. The neurodegenerative disease is a disease selected from the group consisting of Alzheimer's disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, prion diseases, HIV-associated dementia and any form of cognitive disorders linked to neurodegeneration, preferably Alzheimer's disease.

The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine.

The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and / or neuronal death and / or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Deuterated forms of volinanserin according to structural formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.

The present invention relates to novel molecules useful in the prevention, amelioration, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, a-synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurons, such as, but not limited to, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein, Alpha-synuclein and Alpha-synuclein. For example, Parkinson's disease, multi-system atrophy, dementia with Lewy bodies (LBD; dementia with Lewy bodies (DLB) ('pure 'dementia with Lewy bodies), dementia with Parkinson's disease (PDD) or diffuse Lewy body disease. The present invention relates to alpha-synuclein binding molecules, in particular alpha-synuclein antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The molecules of the invention may also be used to determine the predisposition of predisposition to such a condition, disease, or abnormality, to monitor a residual condition, disease, or abnormality, or to predict the responsiveness of a patient suffering from such a condition, disease, or abnormality to a treatment with a certain drug.

This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.

A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.

This disclosure relates to an amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.

There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1):or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II):or a pharmaceutically acceptable salt thereof.

In vitro method for the diagnosis of synucleinopathies. The present invention is directed to an in vitro method for the specific diagnosis of a synucleinopathy and / or for the differential diagnosis of a synucleinopathy from Alzheimer disease (AD). In a preferred embodiment, the synucleinopathy is Dementia with Lewy bodies (DLB) or Parkinson's disease (PD).

Specific polymorphisms in BChE gene have been found which allow determining whether a patient suffers from dementia with Lewy bodies (DLB), and allow distinguishing it from Alzheimer's disease. The invention provides an in vitro method for the diagnosis of DLB comprising determining in a biological sample from a subject, the genotype of the following polymorphisms in butyrylcholinesterase (BChE) gene: the polymorphic site at position 3687 in NCBI Accession Number NG_009031 (i.e. SEQ ID NO: 1 ) the polymorphic site at position 4206 in SEQ ID NO: 1, the polymorphic site at position 4443 in SEQ ID NO: 1. and the polymorphic site at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 26).

The present invention relates to methods of treating Lewy body dementia, multi-system atrophy, or simple autonomic failure in a subject in need thereof. Also provided are compositions for treating dementia with Lewy bodies, multi-system atrophy, or simple autonomic failure.